Recursion announced it has entered into a licensing agreement with the Ohio State Innovation Foundation (OSIF), gaining rights to OSU-HDAC42, a clinical-stage compound that will be developed by Recursion as REC-2282. Recursion plans to develop the compound in neurofibromatosis type 2 (NF2), a devastating rare tumor syndrome. Under the terms of this agreement, Recursion obtains exclusive worldwide rights to develop and commercialize REC-2282.